Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
View/ Open
Date
2018-03ICR Author
Author
Boon, E
van Boxtel, W
Buter, J
Baatenburg de Jong, RJ
van Es, RJJ
Bel, M
Fiets, E
Oosting, SF
Slingerland, M
Hoeben, A
Tesselaar, MET
Jonker, MA
Flucke, UE
Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group
van der Graaf, WTA
van Herpen, CML
Type
Journal Article
Metadata
Show full item recordAbstract
Background Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT).Methods Patients with advanced androgen receptor-positive salivary duct carcinoma treated with first-line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression-free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care.Results Thirty-four of 35 patients who were ADT-treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT-treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P = .02).Conclusion We recommend ADT in advanced androgen receptor-positive salivary duct carcinoma given its response and clinical benefit. © 2017 Wiley Periodicals, Inc. Head Neck, 2017.
Collections
Subject
Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group
Salivary Ducts
Humans
Salivary Gland Neoplasms
Neoplasm Recurrence, Local
Androgen Antagonists
Receptors, Androgen
Treatment Outcome
Registries
Survival Rate
Retrospective Studies
Adult
Aged
Aged, 80 and over
Middle Aged
Netherlands
Female
Male
Research team
Clinical and Translational Sarcoma
Language
eng
Date accepted
2017-10-25
License start date
2018-03
Citation
Head & neck, 2018, 40 (3), pp. 605 - 613